247 related articles for article (PubMed ID: 9620303)
1. The prognostic significance of delayed hypersensitivity to dinitrochlorobenzene and mechlorethamine hydrochloride in cutaneous T cell lymphoma.
Vonderheid EC; Ekbote SK; Kerrigan K; Kalmanson JD; Van Scott EJ; Rook AH; Abrams JT
J Invest Dermatol; 1998 Jun; 110(6):946-50. PubMed ID: 9620303
[TBL] [Abstract][Full Text] [Related]
2. A prospective study of cutaneous intolerance to topical mechlorethamine therapy in patients with cutaneous T-cell lymphomas. French Study Group of Cutaneous Lymphomas.
Estève E; Bagot M; Joly P; Souteyrand P; Beylot-Barry M; Vaillant L; Delaunay M; Avril MF; Laroche L; Grange F; Thomine E; Wechsler J
Arch Dermatol; 1999 Nov; 135(11):1349-53. PubMed ID: 10566833
[TBL] [Abstract][Full Text] [Related]
3. Response of mycosis fungoides to topical chemotherapy with mechlorethamine.
Ramsay DL; Parnes RE; Dubin N
Arch Dermatol; 1984 Dec; 120(12):1585-90. PubMed ID: 6508330
[TBL] [Abstract][Full Text] [Related]
4. Topical chemotherapy and immunotherapy of mycosis fungoides: intermediate-term results.
Vonderheid EC; Van Scott EJ; Johnson WC; Grekin DA; Asbell SO
Arch Dermatol; 1977 Apr; 113(4):454-62. PubMed ID: 848974
[TBL] [Abstract][Full Text] [Related]
5. Improved results of delayed-type hypersensitivity skin testing in HIV-infected patients treated with topical dinitrochlorobenzene.
Smith KJ; Vidmar D; Skelton HG; Hackley BE
J Am Acad Dermatol; 1996 Sep; 35(3 Pt 1):491-3. PubMed ID: 8784300
[No Abstract] [Full Text] [Related]
6. Topical treatment of early cutaneous T-cell lymphoma.
Ramsay DL; Meller JA; Zackheim HS
Hematol Oncol Clin North Am; 1995 Oct; 9(5):1031-56. PubMed ID: 8522483
[TBL] [Abstract][Full Text] [Related]
7. Skin sensitization to 2, 4 dinitrochlorobenzene (DNCB) in the first months of life.
Cassimos C; Kanakoudi-Tsakalidis F; Spyroglou K; Ladianos M; Tzaphi R
J Clin Lab Immunol; 1980 Mar; 3(2):111-3. PubMed ID: 7205930
[TBL] [Abstract][Full Text] [Related]
8. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
9. Mechlorethamine gel for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma.
Talpur R; Venkatarajan S; Duvic M
Expert Rev Clin Pharmacol; 2014 Sep; 7(5):591-7. PubMed ID: 25068889
[TBL] [Abstract][Full Text] [Related]
10. Failure to induce tolerance to mechlorethamine hydrochloride.
Leshaw S; Simon RS; Bear RL
Arch Dermatol; 1977 Oct; 113(10):1406-8. PubMed ID: 911169
[TBL] [Abstract][Full Text] [Related]
11. Improved results of delayed-type hypersensitivity skin testing in HIV-infected patients treated with topical dinitrochlorobenzene.
Stricker RB; Goldberg B; Mills LB; Epstein WL
J Am Acad Dermatol; 1995 Oct; 33(4):608-11. PubMed ID: 7673493
[TBL] [Abstract][Full Text] [Related]
12. Topical dinitrochlorobenzene therapy in the treatment of refractory atopic dermatitis: systemic immunotherapy.
Yoshizawa Y; Matsui H; Izaki S; Kitamura K; Maibach HI
J Am Acad Dermatol; 2000 Feb; 42(2 Pt 1):258-62. PubMed ID: 10642682
[TBL] [Abstract][Full Text] [Related]
13. Topical mechlorethamine therapy for early stage mycosis fungoides.
Ramsay DL; Halperin PS; Zeleniuch-Jacquotte A
J Am Acad Dermatol; 1988 Oct; 19(4):684-91. PubMed ID: 3183094
[TBL] [Abstract][Full Text] [Related]
14. Immunological studies in psoriasis. The quantitative evaluation of cell-mediated immunity in patients with psoriasis by experimental sensitization to 2,4-dinitrochlorobenzene.
Obalek S; Haftek M; Sliński W
Dermatologica; 1977; 155(1):13-25. PubMed ID: 303184
[TBL] [Abstract][Full Text] [Related]
15. Delayed cutaneous hypersensitivity and human renal allotransplantation.
Rolley RT; Sterioff S; Parks LC; Williams GM
Transplant Proc; 1977 Mar; 9(1):81-3. PubMed ID: 325815
[TBL] [Abstract][Full Text] [Related]
16. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a 1-h exposure time to mechlorethamine in patients undergoing topical treatment.
Foulc P; Evrard V; Dalac S; Guillot B; Delaunay M; Verret JL; Dréno B
Br J Dermatol; 2002 Nov; 147(5):926-30. PubMed ID: 12410702
[TBL] [Abstract][Full Text] [Related]
18. Some aspects of cell-mediated hypersensitivity in patients with melanoma.
Moszkowska G; Jassem J; Kondrat W; Kopacz A; Goszczyńska E
Arch Immunol Ther Exp (Warsz); 1980; 28(4):655-60. PubMed ID: 6970028
[TBL] [Abstract][Full Text] [Related]
19. Malignant melanoma and other second cutaneous malignancies in cutaneous T-cell lymphoma. The influence of additional therapy after total skin electron beam radiation.
Licata AG; Wilson LD; Braverman IM; Feldman AM; Kacinski BM
Arch Dermatol; 1995 Apr; 131(4):432-5. PubMed ID: 7726585
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous hypersensitivity and desensitization to mechlorethamine in patients with mycosis fungoides lymphoma.
Waldorf DS; Haynes HA; Van Scott EJ
Ann Intern Med; 1967 Aug; 67(2):282-90. PubMed ID: 6036390
[No Abstract] [Full Text] [Related]
[Next] [New Search]
